| Systemic Sclerosis: A Bird’s Eye Review of Recent Literature |
 |
 |
 |
| Tuesday, 06 July 2010 10:19 |
|
Pathogenesis and new therapeutical targets
Transcription factor Fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis: In this study the authors investigated the potential pathogenetic role of Fos-related antigen-2 (Fra-2) for the peripheral microangiopathy in Fra-2 transgenic (tg) mice and in human systemic sclerosis (SSc) patients. Fra-2 is a transcription factor of the activator protein-1 (AP-1) family involved in the control of stress response including cell proliferation, apoptosis, inflammation, wound healing and tumorigenesis. Login to download your own copy of the full review from the link provided below. |
More articles :
» Preliminary Results Show Beneficial Effects of Imatinib in Scleroderma
Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing beneficial effects on skin and lung manifestations in patients with diffuse cutaneous scleroderma....
» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec
® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...
» ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy
ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.The patent comes nearly two years after it was developed by University of Tennessee Health...
» Rituximab Shows Promise in Scleroderma
Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...
» Medical Research Trends to Watch in 2012
1. NCATS: Who moved my cheese?This year, the National Institutes of Health will establish its new (NCATS), created to speed the translation of basic discoveries into therapies that will improve public health. Solutions can be tough to develop, and...
» PUVA Therapy In The Treatment of Localized Scleroderma
In localized , disease activity would tend to stop spontaneously over time. Treatment is important to reduce disabilities caused by the active phases of disease. According to , there are three treatments used in the treatment of localized...